Archives
-
15-PGDH Inhibition and Muscle Repair During Weight Loss
2026-09-01
A 2026 PNAS study identifies 15-PGDH inhibition as a strategy to improve skeletal muscle regeneration and force recovery during semaglutide-induced weight loss in obese mice. The work shows that combining a 15-PGDH inhibitor with semaglutide enhanced muscle stem cell activity and regenerated myofiber growth without eliminating the drug’s weight-loss effect.
-
Puromycin dihydrochloride: Workflow & Troubleshooting
2026-09-01
Puromycin dihydrochloride combines rapid antibiotic selection with a direct readout of translational stress, making it useful for stable cell-line engineering and ribosome-focused experiments. This guide connects practical puromycin selection design with endothelial apoptosis research while emphasizing kill-curve validation, assay controls, and troubleshooting.
-
IPR-803: Urokinase Receptor Inhibitor Workflow
2026-08-31
IPR-803 connects direct uPAR–uPA interaction testing with invasion, angiogenesis, metastasis, and formulation-aware combination studies. This practical guide distinguishes biochemical potency from cellular activity and provides troubleshooting strategies for breast and pancreatic cancer models.
-
Plk1 Control of p31comet in Checkpoint Disassembly
2026-08-31
The reference study identifies Polo-like kinase 1 (Plk1) as a negative regulator of p31comet-driven mitotic checkpoint complex disassembly. By combining HeLa cell extracts, purified proteins, kinase inhibition, and phosphosite mutagenesis, the authors show that Plk1 phosphorylates p31comet at S102 and prevents premature checkpoint inactivation during active mitosis.
-
HyperScribe T7 Cy3 RNA Labeling Kit Guide
2026-08-30
The HyperScribe T7 High Yield Cy3 RNA Labeling Kit supports tunable fluorescent RNA probe synthesis by T7-driven in vitro transcription. This guide connects label-density decisions with assay physics, RNAi delivery research, in situ hybridization, and Northern blot interpretation.
-
2'3'-cGAMP: STING Assay Workflow & Insights
2026-08-29
Use 2'3'-cGAMP (sodium salt) as a high-affinity benchmark for dissecting STING signaling, type I interferon induction, and compound-response assays. A newer interactome study also supports a practical expansion into Rab18/FosB-dependent cell-migration experiments, helping researchers separate canonical immunity from noncanonical phenotypes.
-
PPARG R212W in Familial Partial Lipodystrophy
2026-08-28
A 2026 study characterizes PPARG R212W in a Chinese family with familial partial lipodystrophy type 3, showing that the variant combines reduced transcriptional activity with accelerated protein degradation and mitochondrial dysfunction. Partial rescue by rosiglitazone supports ligand-based experiments as a way to probe defective PPARγ signaling, while not establishing clinical efficacy.
-
Sulfaphenazole-Derived Sulfonamides for TB
2026-08-28
This 2021 study systematically optimized sulfaphenazole-derived sulfonamides to retain antimycobacterial activity while reducing CYP 2C9 inhibition, a liability associated with drug–drug interaction risk. Compound 10d provided the clearest balance, combining activity against Mycobacterium tuberculosis H37Rv with low CYP 2C9 inhibition and low cytotoxicity.
-
Fenofibrate Workflows for PPARα–YAP Research
2026-08-27
Fenofibrate enables controlled interrogation of PPARα-driven lipid metabolism, hepatocyte growth, and YAP pathway activation in cell and mouse models. This practical guide connects formulation, time-course dosing, pathway readouts, and troubleshooting for metabolic, aging, and cancer biology research.
-
Hydroxytyrosol: Designing Better Redox Assays
2026-08-27
Hydroxytyrosol is an olive-derived antioxidant bioactive compound with value in oxidative stress modulation and cardiovascular health research. This article presents a concentration-aware framework for separating direct redox chemistry from cellular anti-inflammatory and anti-atherogenic effects.
-
Cyclic di-GMP: Biofilm and STING Workflows
2026-08-26
Cyclic di-GMP supports two distinct research paths: dissecting c-di-GMP-dependent biofilm persistence and activating STING in immune modulation research. This practical guide connects product handling, adhesion-stage bacterial assays, and mammalian pathway studies while separating established findings from optimization starting points.
-
Cefiderocol Activity in Resistant European Non-Fermenters
2026-08-26
This ARTEMIS study directly compared cefiderocol with several β-lactam/β-lactamase inhibitor combinations across a large European collection of Pseudomonas aeruginosa and Acinetobacter spp., including isolates resistant to meropenem and newer combination therapies. Its high in vitro susceptibility rates and molecular analysis support parallel susceptibility testing while showing that cefiderocol resistance can involve species-specific changes in iron-uptake pathways.
-
Leucomycin (Kitasamycin): From Ribosome to Translation
2026-08-25
Leucomycin, also known as kitasamycin, is a mechanistically informative macrolide for linking ribosomal inhibition, isolate-level susceptibility, resistance biology, and translational research strategy. Evidence from experimentally infected pigs shows why susceptibility testing must precede claims of therapeutic relevance.
-
Leucomycin In Vitro Antibacterial Activity: 1962 Study
2026-08-25
The 1962 study established a systematic in vitro framework for evaluating leucomycin and its A1 fraction across diverse pathogenic bacteria, with particular attention to erythromycin-resistant staphylococci. Its comparison of antibiotic fractions, culture conditions, pH, and blood components remains useful for interpreting historical activity data and designing modern macrolide resistance and growth-inhibition assays.
-
Cyclic di-GMP Workflows for Biofilm & STING
2026-08-24
Translate cyclic di-GMP biology into practical workflows for biofilm persistence, bacterial genome stability, and STING-focused immune modulation. This guide combines adhesion-stage persister assays with water-based compound handling, cell-free validation, and carefully controlled cancer immunotherapy studies.